文献速递呼吸道感染

糖皮质激素辅助治疗社区获得性肺炎的实用性随机对照试验

A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia
RSS 订阅 · PubMed 顶刊 · 肺炎 · 2025-10-29

在肯尼亚18家公立医院开展的实用性、开放标签随机对照试验纳入2180例社区获得性肺炎(CAP)成人患者,比较标准治疗与加用口服低剂量糖皮质激素10天。30天全因死亡在糖皮质激素组为22.6%,标准治疗组为26.0%(HR 0.84,95%CI 0.73–0.97,P=0.02),不良事件与严重不良事件两组相似。

要点

  • 在低资源地区CAP成人患者中,辅助糖皮质激素与较低30天死亡风险相关。
  • 30天死亡:糖皮质激素组22.6% vs 标准治疗组26.0%(HR 0.84,95%CI 0.73–0.97,P=0.02)。
  • 不良事件与严重不良事件两组相似;考虑与糖皮质激素相关的严重不良事件发生于5例(0.5%)。

核心结论

  • 在低资源地区的社区获得性肺炎成人患者中,辅助糖皮质激素治疗与标准治疗相比与较低的死亡风险相关。

研究设计与样本

  • 实用性、开放标签、随机对照试验,在肯尼亚18家公立医院开展,共2180例患者随机分组(糖皮质激素组1089例,标准治疗组1091例)。
  • 纳入已诊断CAP且无明确糖皮质激素使用指征的成人患者,比较标准治疗与加用口服低剂量糖皮质激素10天。
  • 主要结局为入组后30天全因死亡。

主要发现

  • 患者中位年龄53岁(四分位距38–72),女性占46%。
  • 30天时共530例(24.3%)死亡:糖皮质激素组246例(22.6%),标准治疗组284例(26.0%)。
  • 30天死亡风险比HR 0.84(95%CI 0.73–0.97,P=0.02)。
  • 不良事件与严重不良事件在两组频率相似;考虑与糖皮质激素相关的严重不良事件发生于5例(0.5%)。

临床怎么用

  • 在诊断与治疗设施有限的低资源环境中,对无明确糖皮质激素指征的CAP成人患者,可考虑加用口服低剂量糖皮质激素10天以降低30天死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

N Engl J Med . 2025 Dec 4;393(22):2187-2197. doi: 10.1056/NEJMoa2507100. Epub 2025 Oct 29. ABSTRACT BACKGROUND: Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings with limited diagnostic and treatment facilities is unclear. METHODS: In this pragmatic, open-label, randomized, controlled trial conducted in 18 public hospitals in Kenya, we assigned adult patients who had received a diagnosis of CAP and who did not have a clear indication for glucocorticoids to receive either standard care for CAP or oral low-dose glucocorticoids for 10 days in addition to standard care. The primary outcome was death from any cause at 30 days after enrollment. RESULTS: A total of 2180 patients underwent randomization (1089 assigned to the glucocorticoid group and 1091 to the standard-care group). The median age of the patients was 53 years (interquartile range, 38 to 72); 46% were women. At day 30, deaths were reported in 530 patients (24.3%): 246 patients (22.6%) in the glucocorticoid group and 284 patients (26.0%) in the standard-care group (hazard ratio, 0.84; 95% confidence interval, 0.73 to 0.97; P = 0.02). The frequencies of adverse events and serious adverse events were similar in the two trial groups. Serious adverse events that were considered to be related to glucocorticoid administration occurred in 5 patients (0.5%). CONCLUSIONS: In patients with CAP in a low-resource setting, adjunctive glucocorticoid therapy was associated with a lower risk of death than standard care. (Funded by Wellcome Trust and others; SONIA PACTR number, PACTR202111481740832; ISRCTN number, ISRCTN36138594.). PMID: 41159889 | PMC: PMC12659994 | DOI: 10.1056/NEJMoa2507100

来源:PubMed 顶刊 · 肺炎,查看原文。版权归原作者所有。

引用

  1. PubMed 顶刊 · 肺炎:A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。